Search results for "Adverse effect"

showing 10 items of 1065 documents

Cytotoxic effects of individual and combined sterigmatocystin and nivalenol on liver hepatocellular carcinoma cells

2020

Abstract Since humans are exposed to different mycotoxins through daily intake, there is increasing concern about the adverse effects of the interactions between them. Cytotoxicity of sterigmatocystin (STE) and nivalenol (NIV) alone and in combination in human hepatocarcinoma (HepG2) cells was evaluated by MTT assay. Furthermore, ROS production and alteration of ΔΨm as mechanisms of action were assessed. Cells were treated with concentrations ranging from 0.15 to 5 μM for NIV and from 0.78 to 50 μM for STE individually and in binary combinations. The combination ratio between the mixture STE + NIV was 10:1. The IC50 values of NIV ranged from 0.96 to 0.66 μM, whereas no IC50 values were obta…

endocrine systemCarcinoma HepatocellularSterigmatocystinAntineoplastic AgentsPharmacologyToxicology03 medical and health scienceschemistry.chemical_compound0404 agricultural biotechnologyIc50 valuesmedicineHumansCytotoxic T cellMTT assayCytotoxicityMycotoxinAdverse effect030304 developmental biology0303 health sciencesMolecular StructureLiver NeoplasmsDrug SynergismHep G2 Cells04 agricultural and veterinary sciencesGeneral Medicinemedicine.disease040401 food sciencechemistryHepatocellular carcinomaTrichothecenesFood ScienceSterigmatocystinFood and Chemical Toxicology
researchProduct

Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial.

2011

Background: Lactoferrin is a mammalian milk glycoprotein involved in innate immunity. Recent data show that bovine lactoferrin (bLF) prevents late-onset sepsis in preterm very low birth weight (VLBW) neonates. Methods: This is a secondary analysis of data from a multicenter randomized controlled trial where preterm VLBW neonates randomly received bLF (100 mg/day; group A1), bLF + Lactobacillus rhamnosus GG (106 colony-forming units per day; group A2), or placebo (group B) for 6 weeks. Here we analyze the incidence rates of fungal colonization, invasive fungal infection (IFI), and rate of progression from colonization to infection in all groups. Results: This study included 472 neonates who…

fungal sepsisDiseasesInfant Premature DiseasesPediatricsGastroenterologylactoferrin; VLBW neonates; Candida; fungal sepsis; prophylaxisGroup BSettore MED/38 - Pediatria Generale E SpecialisticaAnti-Infective AgentsInfant Very Low Birth WeightCandidabiologyLactoferrinBovine lactoferrin fungal infections very low birth weight newbornsPerinatology and Child Healthlactoferrinprophylaxismedicine.symptomInfant Prematuremedicine.medical_specialtyFungal sepsisPlaceboSepsisLactobacillus rhamnosusIntolerancesInternal medicinemedicineAnimalsHumansfungal sepsiAdverse effectPrematureProphylaxisbusiness.industryVery Low Birth WeightProbioticsInfant NewbornInfantNewbornbiology.organism_classificationmedicine.diseaseLactoferrinLow birth weightMycosesVLBW neonatesPediatrics Perinatology and Child HealthImmunologyCandida; Fungal sepsis; Lactoferrin; Prophylaxis; VLBW neonates; Animals; Anti-Infective Agents; Cattle; Humans; Infant Newborn; Infant Premature; Infant Premature Diseases; Lactoferrin; Mycoses; Probiotics; Infant Very Low Birth Weight; Pediatrics Perinatology and Child Healthbiology.proteinCattlebusiness
researchProduct

Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM.

2020

Abstract Background In Europe, increases in HCV infection have been observed over the last two decades in MSM, making them a key population for recently acquired HCV. Alternative combinations of direct-acting antiviral agents against early HCV infection need to be assessed. Patients and methods In this pilot trial, MSM with recently acquired genotype 1 or 4 HCV infection were prospectively included and received 8 weeks of oral grazoprevir 100 mg and elbasvir 50 mg in a fixed-dose combination administered once daily. The primary endpoint was sustained virological response evaluated 12 weeks after the end of treatment (EOT) (SVR12). Secondary endpoints were the virological characterization of…

hepatitis C virusCyclopropanesMaleadverse eventmen who have sex with menHepacivirusmedicine.disease_causeSexual and Gender Minoritiesblood HIV RNA0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesfollow-upClinical endpointMedicinePharmacology (medical)infections030212 general & internal medicinehepatitis ceducation.field_of_studySulfonamideshepatitis c rnaImidazolesvirus diseasesHepatitis Cvirologyhepatitis C virus genotype 13. Good healthEuropeInfectious DiseasesGrazoprevirRNA Viral030211 gastroenterology & hepatologyDrug Therapy CombinationMicrobiology (medical)medicine.medical_specialtyElbasvirGenotypeHepatitis C virusPopulationelbasvirAntiviral Agentsreinfection03 medical and health sciencesInternal medicineQuinoxalinesHumansHomosexuality MaleAdverse effecteducationplasmasuicideBenzofuransPharmacologybusiness.industrySurrogate endpointHIVgrazoprevirHepatitis C Chronicmedicine.diseaseAmidessurrogate endpoints[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyQuality of LifeCarbamatesbusinessThe Journal of antimicrobial chemotherapy
researchProduct

Effect of using cardiovascular risk scoring in routine risk assessment in primary prevention of cardiovascular disease: an overview of systematic rev…

2019

Background Our objectives were to critically appraise and summarise the current evidence for the effectiveness of using cardiovascular disease (CVD) risk scoring (total risk assessment - TRA) in routine risk assessment in primary prevention of CVD compared with standard care with regards to patients outcomes, clinical risk factor levels, medication prescribing, and adverse effects. Methods We carried out an overview of existing systematic reviews (SRs). Presentation of the results aligned guidelines from the PRISMA statement. The data is presented as a narrative synthesis. We searched MEDLINE (Ovid), EMBASE, CENTRAL and SCOPUS databases from January 1990 to March 2017, reviewed the referenc…

lcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_specialtyMEDLINEDisease030204 cardiovascular system & hematologyDecision Support Techniques03 medical and health sciences0302 clinical medicineMeta-Analysis as TopicPredictive Value of TestsmedicineHumans030212 general & internal medicineAdverse effectAngiologyRisk assessmentPrimary preventionbusiness.industryPrognosisCardiovascular systemSystematic reviewBlood pressureCardiovascular diseasesRisk factorslcsh:RC666-701Emergency medicineObservational studyCardiology and Cardiovascular MedicineRisk assessmentbusinessSystematic Reviews as TopicResearch ArticleBMC Cardiovascular Disorders
researchProduct

A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refract…

2018

ABSTRACT We assessed the tolerability and antitumor activity of solitomab, a bispecific T-cell engager (BiTE®) antibody construct targeting epithelial cell adhesion molecule (EpCAM). Patients with relapsed/refractory solid tumors not amenable to standard therapy received solitomab as continuous IV infusion in a phase 1 dose-escalation study with six different dosing schedules. The primary endpoint was frequency and severity of adverse events (AEs). Secondary endpoints included pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity. Sixty-five patients received solitomab at doses between 1 and 96 µg/day for ≥28 days. Fifteen patients had dose-limiting toxicities (DLTs): e…

lcsh:Immunologic diseases. Allergy0301 basic medicinemedicine.medical_specialtyImmunologyAMG 110bispecificlcsh:RC254-282Gastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineSolitomabRefractoryPharmacokineticsInternal medicineImmunology and AllergyMedicineAdverse effectOriginal Researchbusiness.industryEpCAM phase 1Epithelial cell adhesion moleculesolitomablcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensBiTE®CD3Discontinuation030104 developmental biologyMT110OncologyTolerabilitychemistry030220 oncology & carcinogenesisPharmacodynamicssolid tumorimmunotherapylcsh:RC581-607businessOncoimmunology
researchProduct

Effect of allergen-specific immunotherapy with purified Alt a1 on AMP responsiveness, exhaled nitric oxide and exhaled breath condensate pH: a random…

2010

Abstract Background Little information is available on the effect of allergen-specific immunotherapy on airway responsiveness and markers in exhaled air. The aims of this study were to assess the safety of immunotherapy with purified natural Alt a1 and its effect on airway responsiveness to direct and indirect bronchoconstrictor agents and markers in exhaled air. Methods This was a randomized double-blind trial. Subjects with allergic rhinitis with or without mild/moderate asthma sensitized to A alternata and who also had a positive skin prick test to Alt a1 were randomized to treatment with placebo (n = 18) or purified natural Alt a1 (n = 22) subcutaneously for 12 months. Bronchial respons…

lcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinemedicine.medical_specialtyPathologyAllergybusiness.industrymedicine.medical_treatmentResearchInflammationGeneral MedicineImmunotherapyPlacebomedicine.diseaseGastroenterologyInternal medicineExhaled nitric oxidemedicineImmunology and AllergyMethacholineExhaled breath condensatemedicine.symptomAdverse effectbusinesslcsh:RC581-607medicine.drugAllergy, Asthma & Clinical Immunology
researchProduct

Combined oral prolonged-release oxycodone and naloxone in chronic pain management

2013

Introduction: The use of opioids is associated with unwanted adverse effects, particularly opioid-induced constipation (OIC). The adverse effects of opioids on gastrointestinal function are mediated by the interaction with opioid receptors in the gastrointestinal tract. The most common drugs used for relieving OIC are laxatives, which do not address the opioid receptor-mediated bowel dysfunction and do not provide sufficient relief. Areas covered: This paper discusses the role of a combination of prolongedrelease formulation of oxycodone (OX) and naloxone (N) in the prevention and management of OIC, reporting efficacy and safety outcome of controlled studies. In a therapeutic area of great …

medicine.drug_classSettore MED/41 - Anestesiologiacancer pain chronic pain opioid-antagonist opioids oxycodone--naloxone combinationNaloxonemedicineHumansPharmacology (medical)Adverse effectPharmacologybusiness.industryNaloxoneChronic painGeneral Medicinemedicine.diseaseAnalgesics OpioidDrug CombinationsTreatment OutcomeOpioidAnesthesiaDelayed-Action PreparationsChronic PainGastrointestinal functionbusinessCancer painOxycodoneOpioid antagonistOxycodonemedicine.drug
researchProduct

2019

Background: Physical inactivity is a major risk factor for nonalcoholic fatty liver disease (NAFLD). Exercise-based prevention interventions for improving cardiorespiratory fitness are a recommended complementary treatment for NAFLD. Achievement of minimally effective physical activity to improve cardiorespiratory fitness among patients typically involves high personal and financial expenses in face-to-face settings. We designed an eHealth approach for patients with NAFLD to improve the cardiorespiratory fitness and report the first results of the HELP (Hepatic Inflammation and Physical Performance in Patients With NASH [nonalcoholic steatohepatitis]) study. Objective: We aimed to assess th…

medicine.medical_specialty020205 medical informaticsbusiness.industryFatty liverPsychological interventionVO2 maxHealth InformaticsCardiorespiratory fitness02 engineering and technologymedicine.diseaseEndurance trainingNonalcoholic fatty liver disease0202 electrical engineering electronic engineering information engineeringmedicinePhysical therapyRisk factorAdverse effectbusinessJournal of Medical Internet Research
researchProduct

The role of interventional radiology in the management of abnormally invasive placenta: a systematic review of current evidences

2020

Abnormally invasive placenta (AIP) is a potentially severe condition. To date, arterial embolization in women with postpartum hemorrhage due to AIP is the treatment option for which highest degrees of evidence are available. However, other techniques have been tested, including prophylactic catheter placement, balloon occlusion of the iliac arteries and abdominal aorta balloon occlusion. In this systematic review, we provide an overview of the currently reported interventional radiology procedures that are used for the treatment of postpartum hemorrhage due to AIP and suggest recommendations based on current evidences. Owing to a high rate of adverse events, prophylactic occlusion of intern…

medicine.medical_specialty030219 obstetrics & reproductive medicineHysterectomymedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentArterial Embolization[SDV]Life Sciences [q-bio]Abdominal aortaInterventional radiologyReview Article3. Good health030218 nuclear medicine & medical imagingSurgery03 medical and health sciences0302 clinical medicineUterine artery embolizationmedicine.arteryOcclusionmedicineRadiology Nuclear Medicine and imagingEmbolizationbusinessAdverse effectComputingMilieux_MISCELLANEOUS
researchProduct

Is diabetes the cost to pay for a greater cardiovascular prevention?

2010

The recent JUPITER (Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin) trial is another study providing evidence about the effectiveness of statin therapy in reducing cardiovascular risk. Yet, in this study significantly higher glycated hemoglobin levels and incidence rates of diabetes were observed in persons treated with rosuvastatin than the placebo group. It should be noted that adverse effects on glucose metabolism have already been reported, albeit rarely, in previous trials with statins. Although the exact mechanisms involved are unknown, it seems that statins may deteriorate glycemic control by decreasing different metabolites,…

medicine.medical_specialty10265 Clinic for Endocrinology and Diabetology610 Medicine & healthDiabete2705 Cardiology and Cardiovascular Medicinechemistry.chemical_compoundDiabetes mellitusInternal medicinemedicineDiabetes MellitusHumansRosuvastatinRisk factorRosuvastatin CalciumAdverse effectGlycemicSulfonamidesbusiness.industryPreventionIncidence (epidemiology)Statinsnutritional and metabolic diseasesCardiovascular riskmedicine.diseaseFluorobenzenesRosuvastatin CalciumEndocrinologyPyrimidineschemistryCardiovascular DiseasesAtherosclerosilipids (amino acids peptides and proteins)Glycated hemoglobinHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular Medicinebusinessmedicine.drug
researchProduct